Last €78.70 EUR
Change Today -0.14 / -0.18%
Volume 4.5K
BIM On Other Exchanges
BIM is not on other exchanges.
As of 5:29 AM 04/25/14 All times are local (Market data is delayed by at least 15 minutes).

biomerieux (BIM) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/7/14 - €82.87
52 Week Low
10/18/13 - €70.65
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOMERIEUX (BIM)

Related News

No related news articles were found.

biomerieux (BIM) Related Businessweek News

No Related Businessweek News Found

biomerieux (BIM) Details

bioMérieux SA, together with its subsidiaries, is engaged in the design, development, manufacture, and marketing of in vitro diagnostic systems. The company’s diagnostic systems consist of reagents and consumables to conduct biological tests for use in performing screening, diagnostic assistance, prognosis, and treatment monitoring; instruments used for automated testing at high or low throughputs; software to process and interpret the results of biological tests; and related services, such as the installation and maintenance of instruments, user training, or the audit of laboratory workflows. It offers diagnostic systems for clinical applications, including the diagnosis of infectious diseases, such as hepatitis, HIV, tuberculosis, and respiratory infections, as well as cardiovascular diseases and targeted cancers based on the analysis of biological samples, such as blood, saliva, and urine; and for industrial applications comprising the analysis of microbiological manufacturing, such as food, water, pharmaceuticals, cosmetics, and biotechnology. The company sells its products through a network of distributors. It has operations in Europe, the Middle East, Africa, North America, Asia-Pacific, and Latin America. The company was founded in 1963 and is based in Marcy l'Etoile, France.

7,723 Employees
Last Reported Date: 03/19/14
Founded in 1963

biomerieux (BIM) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €413.9K
Compensation as of Fiscal Year 2012.

biomerieux (BIM) Key Developments

bioMérieux SA Reports Consolidated Financial Results for the First Quarter Ended March 31, 2014

bioMérieux SA reported consolidated financial results for the first quarter ended March 31, 2014. For the quarter, net sales amounted to EUR 371 million, up a reported 3.3% from EUR 359 million in first-quarter 2013. Organic growth (at constant exchange rates and scope of consolidation) stood at 4.1%, lifted by favorable prior-year comparatives. In addition, consolidated sales included the EUR 14 million in sales of BioFire as from January 16, driving a 7.9% increase in sales at constant exchange rates. Net debt as of March 31, 2014, after payment of the EUR 355 million consideration for the acquisition of BioFire, net debt stood at EUR 322 million.

Alexandre Mérieux Assumes Role of bioMérieux's Chief Executive Officer and Head of Its Management Committee

Alexandre Mérieux will take on the role of Chief Executive Officer of bioMérieux and head its Management Committee. To step up the rollout of its strategic plan, a new organization is being deployed. The Management Committee, led by Alexandre Mérieux, is in charge of implementing the strategy decided by bioMérieux's Board of Directors, which remains chaired by Jean-Luc Belingard. The Committee's main missions are to define the priority action and development areas, oversee strategic projects and allocate the necessary resources to the different departments within the Group. The Business Development, Molecular Biology and Quality departments will report to Jean-Luc Belingard. All other departments, including Investor Relations, will report to Alexandre Mérieux.

bioMérieux SA Recommends Dividend for the Year Ended December 31, 2013 Payable on June 6, 2014; Reports Audited Consolidated Earnings Results for the Year Ended December 31, 2013; Provides Earnings Guidance for the Year 2014

The Board of Directors of bioMérieux SA will recommend that shareholders at the Annual Meeting on May 28, 2014 approve a dividend of EUR 1.00 per share for the year ended December 31, 2013, up 2% from the dividend of EUR 0.98 per share paid in 2012. It represents a total payout of EUR 39.5 million, and will be paid on June 6, 2014. The company reported audited consolidated earnings results for the year ended December 31, 2013. For the year, the company reported sales of EUR 1,588 million compared to EUR 1,570 million a year ago. Operating income before non-recurring items was EUR 262 million compared to EUR 260 million a year ago. Operating income was EUR 257 million compared to EUR 235 million a year ago. Net income of consolidated companies was EUR 165 million or EUR 4.16 per basic and diluted share compared to EUR 134 million or EUR 3.41 per basic and diluted share a year ago. EBITDA was EUR 353 million compared to EUR 355 million a year ago. Free cash flow was EUR 109 million compared to EUR 134 million a year ago. Net cash flow from operations was EUR 240.5 million compared to EUR 258.5 million a year ago. Purchase of property, plant and equipment was EUR 131.1 million compared to EUR 127.4 million a year ago. Net financial expense amounted to EUR 14 million, including the EUR 3.9-million cost of net debt and EUR 10.1 million in other financial expense. The company expects to drive sales growth of between 3% and 5% in 2014, at constant exchange rates and scope of consolidation. The company expected to generate around EUR 60 million in sales in 2014, while its contribution to the growth in consolidated sales will be reported in "changes in the scope of consolidation" for the year. Contributive operating income before non-recurring items of between EUR 220 million and EUR 245 million, after recognition of company’s recurring operations, the investments required at the Durham site and the currency effect (at least an estimated EUR 25 million on the basis of current exchange rates).


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIM:FP €78.70 EUR -0.14

BIM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $35.84 USD -0.43
Bio-Rad Laboratories Inc $124.00 USD -0.02
Hologic Inc $20.73 USD +0.25
QIAGEN NV €15.21 EUR +0.08
Siemens Ltd 740.30 INR -6.60
View Industry Companies

Industry Analysis


Industry Average

Valuation BIM Industry Range
Price/Earnings 18.9x
Price/Sales 2.0x
Price/Book 2.5x
Price/Cash Flow 18.9x
TEV/Sales 1.4x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMERIEUX, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at